On 1000-fold pharmaceutical price markups and why drugs cost more in the United States than in Mexico

American Journal of Medicine

Volumn 128, Issue 12, 2015, Pages 1265-1267

  Boyer, Leslie V ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SNAKE VENOM ANTISERUM; VENOM ANTISERUM;

ARTICLE; CONFLICT OF INTEREST; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG MANUFACTURE; DRUG MARKETING; GOOD MANUFACTURING PRACTICE; HEALTH CARE COST; HEALTH CARE SYSTEM; HOSPITAL CHARGE; HUMAN; MEXICO; PHARMACY; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; SNAKEBITE; UNITED STATES; DRUG INDUSTRY; ECONOMICS; FINANCIAL MANAGEMENT;

ANTIVENINS; DRUG COSTS; DRUG INDUSTRY; FINANCING, GOVERNMENT; HUMANS; MEXICO; UNITED STATES;

EID: 84947868428     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2015.08.007     Document Type: Editorial

References (12)

1. C. Ingraham This $153,000 rattlesnake bite is everything wrong with American health care The Washington Post July 20, 2015 Available at: http://www.washingtonpost.com/news/wonkblog/wp/2015/07/20/this-153000-rattlesnake-bite-is-everything-wrong-with-american-health-care/ Accessed August 5, 2015
2. R.C. Dart, S.A. Seifert, L. Carroll, and et al. Affinity-purified, mixed monospecific crotalidae antivenom ovine Fab for the treatment of crotalid venom poisoning Ann Emerg Med 30 1997 33 39
3. R.C. Dart, S.A. Seifert, L.V. Boyer, and et al. A randomized multicenter trial of Crotaline polyvalent immune Fab (ovine) for the treatment of Crotaline snakebite in the United States Arch Intern Med 161 2001 2030 2036
4. L.V. Boyer, P.B. Chase, J.A. Degan, and et al. Subacute coagulopathy in a randomized, comparative trial of Fab and F(ab')2 antivenoms Toxicon 74 2013 101 108
5. S.P. Bush, A.M. Ruha, S.A. Seifert, and et al. Comparison of F(ab')2 versus Fab antivenom for pit viper envenomation: a prospective, blinded, multicenter, randomized clinical trial Clin Toxicol (Phila) 53 2015 37 45
6. L.V. Boyer, A.A. Theodorou, R.A. Berg, and et al. Antivenom for critically ill children with neurotoxicity from scorpion stings N Engl J Med 360 2009 2090 2098
7. L.V. Boyer, A.T. Theodorou, P.B. Chase, and et al. Effectiveness of Centruroides scorpion antivenom compared to historical controls Toxicon 76 2013 377 385
8. Boyer LV. Emergency treatment of coral snake envenomation with antivenom. Available at: https://clinicaltrials.gov/ct2/show/NCT01337245?term=coral+snake&rank=1. Accessed August 5, 2015.
9. M. Bakall, E.P. Armstrong, G.H. Skrepnek, and L. Boyer Is scorpion antivenom cost-effective as marketed in the United States? Toxicon 76 2013 394 398
10. Carroll J, Staton T. November 27, 2012. 10 Top Drug Launch Disasters: Payer Risk Looms Large as Biopharma Marketing Snafus Highlight Industry's Achilles' Heel. FiercePharma. Available at: http://www.fiercepharma.com/special-reports/rare-disease-therapeutics-anascorp-top-10-drug-launch-disasters. Accessed August 5, 2015.
11. Alltucker K. Scorpion sting leaves Ahwatukee woman with a big bill. The Republic/azcentral.com; September 4, 2012. Available at: http://www.azcentral.com/community/ahwatukee/articles/2012/08/31/20120831scorpion-sting-leaves-woman-big-bill.html?nclick-check=1. Accessed November 8, 2012.
12. L. Wade For Mexican antivenom maker, US market is a snake pit Science 343 2014 16 17